Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients?
Authors:
- Edgardo Mengual-MorenoEMEdgardo Mengual-Moreno
- Manuel NavaMNManuel Nava
- Alexander ManzanoAMAlexander Manzano
- Daniela ArizaDADaniela Ariza
- Luis D’marcoLuis D’marco
- Ana CastroACAna Castro
- María A. MarquinaMMMaría A. Marquina
- Marlon HernándezMarlon Hernández
- Carlos Corredor-PereiraCCCarlos Corredor-Pereira
- Ana Checa-RosAna Checa-Ros
- Valmore BermúdezVBValmore Bermúdez
Open Access
- 26 January 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (2) , 283
Abstract
The novel disease produced by SARS-CoV-2 mainly harms the respiratory tract, but it has shown the capacity to affect multiple organs. Epidemiologic evidence supports the relationship between Coronavirus Disease 2019 (COVID-19) and pancreatic and hepatic injury development, identified by alterations in these organ function markers. In this regard, it is important to ascertain how the current prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) might affect COVID-19 evolution and complications. Although it is not clear how SARS-CoV-2 affects both the pancreas and the liver, a multiplicity of potential pathophysiological mechanisms seem to be implicated; among them, a direct viral-induced injury to the organ involving liver and pancreas ACE2 expression. Additionally, immune system dysregulation, coagulopathies, and drugs used to treat the disease could be key for developing complications associated with the patient’s clinical decline. This review aims to provide an overview of the available epidemiologic evidence regarding developing liver and pancreatic alterations in patients with COVID-19, as well as the possible role that NAFLD/NASH might play in the pathophysiological mechanisms underlying some of the complications associated with COVID-19. This review employed a comprehensive search on PubMed using relevant keywords and filters. From the initial 126 articles, those aligning with the research target were selected and evaluated for their methodologies, findings, and conclusions. It sheds light on the potential pathophysiological mechanisms underlying this relationship. As a result, it emphasises the importance of monitoring pancreatic and hepatic function in individuals affected by COVID-19.Keywords
This publication has 130 references indexed in Scilit:
- Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for PathogenesisThe Journal of Infectious Diseases, 2013
- Classification of acute pancreatitis—2012: revision of the Atlanta classification and definitions by international consensusGut, 2012
- Lipotoxicity Causes Multisystem Organ Failure and Exacerbates Acute Pancreatitis in ObesityScience Translational Medicine, 2011
- Drug induced pancreatitisBest Practice & Research Clinical Gastroenterology, 2010
- Ischemic acute pancreatitis: clinical features of 11 patients and review of the literatureThe American Journal of Surgery, 2009
- Binding of SARS coronavirus to its receptor damages islets and causes acute diabetesActa Diabetologica, 2009
- Drug-Induced Acute Pancreatitis: An Evidence-Based ReviewClinical Gastroenterology and Hepatology, 2007
- Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARSDiabetic Medicine, 2006
- Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathwaysThe Journal of Pathology, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004